Coverage
-
October 23, 2012
Mylan Pharmaceuticals Inc. on Tuesday lost its bid to block Watson Laboratories Inc.'s production of a generic version of diabetes drug Actos while it appeals to the D.C. Circuit a Washington federal judge's Monday order directing the U.S. Food and Drug Administration to immediately approve the generic drug.
2 other articles on this case.
View all »